



Cite this: *Analyst*, 2019, **144**, 114

Received 14th August 2018,  
Accepted 22nd October 2018

DOI: 10.1039/c8an01572d

[rsc.li/analyst](http://rsc.li/analyst)

## Molecular methods in electrochemical microRNA detection

Philip Gillespie,  Sylvain Ladame  and Danny O'Hare  \*

High-throughput profiling/sensing of nucleic acids has recently emerged as a highly promising strategy for the early diagnosis and improved prognosis of a broad range of pathologies, most notably cancer. Among the potential biomarker candidates, microRNAs (miRNAs), a class of non-coding RNAs of 19–25 nucleotides in length, are of particular interest due to their role in the post-transcriptional regulation of gene expression. Developing miRNA sensing technologies that are quantitative, ultrasensitive and highly specific has proven very challenging because of their small size, low natural abundance and the high degree of sequence similarity among family members. When compared to optical based methods, electrochemical sensors offer many advantages in terms of sensitivity and scalability. This non-comprehensive review aims to break-down and highlight some of the most promising strategies for electrochemical sensing of microRNA biomarkers.

## Introduction

MicroRNAs (miRNAs) are short non-coding, single-stranded sequences of RNA, approximately 19–25 nucleotides long, with

Department of Bioengineering, Imperial College London, South Kensington Campus, London, SW72AZ, UK. E-mail: [d.ohare@imperial.ac.uk](mailto:d.ohare@imperial.ac.uk)



**Philip Gillespie**

*Philip Gillespie MPharm is a PhD student in the Department of Bioengineering at Imperial College London. Prior to this, he received his MPharm Degree at the University of East Anglia in 2015 and became a professionally qualified pharmacist in 2016. His research interests are in nucleic acid structure, biosensing, and simulation.*



**Sylvain Ladame**

*Dr Sylvain Ladame (FRSC) received his PhD in Chemistry of Biomolecules from the University of Toulouse (France) in 2001 before moving to Cambridge (U.K.) to work for five years as a post-doctoral researcher in the group of Sir Prof. Shankar Balasubramanian. In 2006, he started his independent research career as a junior group leader with the Institute of Science and Supramolecular Engineering (ISIS, Strasbourg, France) before being appointed lecturer at Imperial College London in 2010 where he is currently employed as a senior lecturer in biosensor development within the Department of Bioengineering. SL has worked in the field of nucleic acids for over fifteen years and now specialises in the engineering and validation of novel non-invasive and low-cost diagnostic tests based on the detection of circulating, cell-free nucleic acids (DNA and RNA) in liquid biopsies. Applications range from early diagnosis and improved prognosis of prostate cancer to early prediction of pre-term birth. SL has published over 50 papers and has two patents to his name.*

length and sequence variation.<sup>1</sup> They are found intra and extra cellularly in plants, animals and humans. Specific alterations in their expression profiles have been correlated with many diseases, including cancer, fitting the IUPAC definition of biomarkers.<sup>2–11</sup> Cost-effective technologies for blood-based, sensitive and specific detection of miRNA biomarkers could potentially transform the way cancer is diagnosed and treated, assuming they are compatible with widespread public screening.<sup>12</sup> In diagnostics, short times to results (TTR) arising from point of care testing (POCT) have been found to improve patient outcomes.<sup>13</sup> Comparable molecular techniques can be used in both optical and electrochemical detection, often leading to similar limits of detection and dynamic ranges.<sup>14,15</sup>

The clear majority of clinically used POCT methods (most notably blood glucose monitoring) are based on electrochemical detection. This is mainly due to enhanced scalability of readout devices in comparison to optical-based detection methods. This review therefore focuses on electrochemical techniques associated with microRNA detection.

Electrochemical methods encompass a broad variety of measurements that can be made on a system. A detailed explanation of each is beyond the scope of this review and there are many good primers on them.<sup>16–19</sup> The IUPAC definition of electrochemical biosensors identifies four signal transduction types: amperometric, potentiometric, impedimetric, and ion charge/field effect.<sup>20</sup> Amperometric sensors involve applying an electrical potential (or a potential/time wave) to a working electrode while measuring the resulting current or current-voltage characteristics. Subsets of these methods include: chronoamperometry (CA), cyclic voltammetry (CV), linear sweep voltammetry, differential pulse voltammetry (DPV) and square wave voltammetry (SWV). Such sensors comprise the bulk of the literature reports. Potentiometric sensors measure the equilibrium potential difference between two electrodes in solution, usually with no current flowing, and typically relate

electrochemical cell potential to the potential drop across a membrane which interacts selectively with the target analyte. Few microRNA biosensors use this technique.<sup>21,22</sup> Impedance-based techniques measure the complex impedance resistance of the electrode–electrolyte solution interface. Double-layer capacitance, charge transfer resistance and diffusional impedance are extracted by fitting the data to model circuits. Changes to these fitting parameters can be correlated with molecular recognition events. Many papers have used such techniques for signal transduction; and this can be used for label free detection.<sup>23–31</sup> Field effect transistors (ion selective field effect transistors, ISFETs or CHEMFETs) measure the dependence of the source–drain current. Transduction arises from the change in charge density on the gate as its chemistry interacts with the target.

Herein, we present an overview of strategies in electrochemical biosensor design applied to microRNA detection. After a brief introduction on the biogenesis of microRNAs and their endogenous forms, the bulk of this review focuses on the molecular approaches capable of quantitatively transducing sequence-specific microRNA binding events into electrochemical signals. The methods discussed are by no means mutually exclusive, and a key to achieving high sensitivity, large dynamic range and high specificity appears to be combining techniques intelligently.

## Biological background of microRNA


In animal cells, miRNAs are synthesised in the nucleus of cells *via* transcription.<sup>1,32</sup> As shown in Fig. 1, this forms a pri-miRNA hairpin structure, which is cleaved by the enzyme Drosha to form pre-miRNA. This pre-miRNA exists as a hairpin, with a 3' overhang. This 3' overhang targets the pre-miRNA for export from the nucleus by Exp5 protein. In the cytoplasm, the pre-miRNA loop is cleaved by enzyme Dicer to leave a double-stranded duplex. The active strand becomes complexed to Ago proteins and the inactive strand dissociates



Danny O'Hare

*Dr Danny O'Hare FRSC graduated in chemistry from Imperial College. He then undertook doctoral work on the development of electrochemical sensors for biomedical applications in the Physiological Flow Studies Unit at Imperial. After postdoctoral work he took his first academic position in the School of Pharmacy, University of Brighton as senior lecturer in analytical sciences. He took up his current*

*appointment in the Department of Bioengineering, Imperial College in 2001 where he is currently reader in sensor research. His research interests are in electrochemical sensors in biomedicine, microfabrication, diagnostics and environmental analysis.*



**Fig. 1** Schematic representation of microRNA biogenesis in animal cells.

and is degraded. The mature microRNA becomes available to bind to cytoplasmic messenger RNA (mRNA) and inhibit their translation. Altered expression of miRNAs has been frequently reported in cancer and has shown great promise as tissue-based markers for cancer classification. Approximately 3% of human genes encode for miRNAs and about 30% of human protein-coding genes may be regulated by these molecules. It is now well established that miRNAs play an important role in various cellular processes such as cell differentiation, cell growth, and cell death. Tumour-derived miRNAs in serum or plasma are emerging as novel blood-based fingerprints for the detection of human cancers, especially at an early stage *via* non-invasive or minimally invasive diagnostic tools. These miRNAs can potentially be detected and quantified not only in frozen tissues but also in serum, plasma, urine, saliva and other body fluids. Interestingly, miRNAs present in human serum proved extremely stable even in harsh conditions of pH (from 1 to 13) and temperature (from freezing to boiling conditions) and significantly more resistant to RNase activity than tissue or cellular miRNAs. To summarise, the correlation between miRNA expression profiles and specific types of cancers or pathogenic conditions, their remarkable stability and their relatively easy accessibility in patient samples in a non-invasive manner could make them ideal cancer biomarkers with enormous potential.

## Key challenges to microRNA detection

MicroRNA sensing faces many technical challenges before considering full implementation in a clinical or laboratory setting. MiRNAs have only been recently discovered and consequently many unknowns remain, most notably about their localisation and endogenous concentration. The current lack of standardised protocols for extracting, processing and quantifying miRNAs has resulted in major inconsistencies in the recent literature.

First and foremost challenge is the low and unknown level of microRNA to detect.<sup>33</sup> How abundant and under which form(s) circulating miRNAs exist in blood are two critical questions for which we are yet to find answers. Currently most changes to specific microRNA levels are reported as up- or down-regulation between healthy and disease states. There is little to no mention of absolute concentrations in biological samples. This is partly due to the lack of suitable analytical tools and of standardised protocols to detect miRNAs, making it extremely difficult to draw quantitative comparisons between studies carried out under slightly different conditions. This may also be due to the intrinsic properties of these miRNAs that can be either free in solution, trapped into exosomes or complexed with one or more proteins. For instance, some studies have reported high concentration of miRNAs in exosomes, while others have shown an average of less than one miRNA molecule per exosome. As a result, to date, it is impossible to confidently answer the question of how sensitive a technology needs to be to detect endogenous miRNAs. The

limit of detection and dynamic range of the miRNA sensor will therefore be highly dependent on the nature of the biofluid being tested (*e.g.* whole blood, serum or plasma) and on the way this fluid is processed prior to analysis.

Normalisation is also a key issue when considering miRNA as quantitative biomarkers. Like for many other biological molecules, the absolute level of expression of certain miRNAs is likely to be influenced by variables that include circadian rhythm, physical activity and diet, thus highlighting the need for strict control of the pre-analytical phase.

Another commonly reported challenge is the miRNAs' short length and high sequence homology between family members. Sequence specificity is therefore important, and most papers will report whether their biosensor can distinguish between miRNAs that differ by a single base mismatch. Studies have shown not all mismatches are equal, and the position of mismatches has a stronger destabilising effect in the middle of sequences in comparison to the ends.<sup>34,35</sup> RNA:DNA and DNA:DNA mismatches are not necessarily equivalent, and therefore mismatch detection assays should be performed with variations on the target miRNA, and not with more stable DNA.<sup>36</sup> Synthetic oligonucleotide analogues such as Peptide Nucleic Acid (PNA), locked nucleic acid (LNA), or phosphorothioate oligonucleotide (PTO) represent a valuable alternative to standard DNA or RNA.<sup>37</sup> This is because of their ability to (i) hybridise more tightly to complementary sequences and (ii) be more responsive to point mutations.

## The ideal microRNA biosensor

The ideal microRNA sensor is dependent on the perceived use. A clear distinction should be made between point of care and laboratory use. Developing a (bio)sensor for point-of-care testing demands its use to be by somebody who is minimally trained, impatient and unable to pre-process samples.<sup>13,38</sup> A laboratory biosensor will be used by a trained professional able to perform sample preparation steps and able to wait for a result. It appears obvious that the laboratory setting would be the "low hanging fruit" of sensing. However, there are already many powerful laboratory methods for detecting microRNAs. Quantitative reverse transcriptase PCR (RT-qPCR) is the gold standard here, however microarrays, northern blotting and next generation sequencing are also powerful methods. PCR-based technologies appear to be ubiquitous in biological labs, which in combination with their versatility for detecting sequences of different lengths, begs the question "why change?" Any new sensing technology for laboratory use must therefore pose significant (economic and/or practical) advantages for the end user. For instance, both amplification steps in RT-qPCR come with associated risks of contamination and error and sensing probes are costly and often suffer from high and variable background noise. The short sequence length and high sequence homology of miRNA compounds some of these issues, requiring careful and intelligent PCR probe design to circumvent.<sup>39,40</sup>

For point of care use, ideal miRNA sensors will provide a quantitative readout in near real-time with high accuracy, will require no sample preparation, and most importantly, will be fit for a diagnostic purpose. The validation of prototypes and devices with clinical samples is therefore a critical step towards having a microRNA biosensor which is translatable into a technology usable in the field. A low number of steps, long shelf life and ease of storage are also very important here.

## Molecular recognition

An electrochemical sensor transduces a molecular recognition event into a measurable electrical signal. The readout can only happen with these two key components combined.<sup>18</sup> Molecular recognition of microRNA is most commonly achieved through complementary Watson–Crick base-pairing using either DNA oligonucleotide or oligonucleotide analogue probes. Most biosensors mentioned in this review are amperometric. They therefore rely on the oxidation or reduction of a molecule to generate a readout signal. As will be discussed in the sections below, this molecule is often part of, or attached to the microRNA target. However, this is not the only option. Often the microRNA acts indirectly within the biosensor, creating the signal from another separate molecule.

## Labelling with a redox probe

A simple and straightforward approach to introduce the source of the electrochemical signal is *via* a so-called labelled signal probe. This idea lends itself to a sandwich sensor type design (Fig. 2), where immobilised capture probes are used alongside reporter probes containing the redox active molecule. This technique has not been used in recent years to detect microRNAs, possibly due to the low concentrations of analyte present and the short length of the miRNA preventing simultaneous hybridisation of both capture and signal probes to the same miRNA strand. However, when combined with amplification strategies, these techniques have proven to be fruitful.<sup>14,41,42</sup>

### Direct labelling of microRNA

Direct labelling of microRNA is another option that has been exploited. Bartosik *et al.* modified all RNAs in a sample by

introduction of Osmium IV 2′2-bipyridine ligands at their 3′ end, followed by selectively capturing the target sequence onto an electrode using a complementary capture probe.<sup>43</sup> Gao *et al.* also directly modified RNA bases with ruthenium complexes, which offers the advantage of creating many electroactive species per microRNA molecule.<sup>44</sup> This again used an immobilised DNA capture probe to hold the microRNA at the electrode surface. Both these techniques used direct labelling of the entire sample, followed by selective immobilisation of the only microRNA sequence of interest at the electrode surface. The major drawback of direct labelling is the additional sample preparation needed to create a signal.

### Guanine oxidation

An alternative to labelling the microRNA target with redox probes is to use the oxidation of its guanine residues as a signal.<sup>45–47</sup> DNA capture probes can be immobilised onto an electrode, using electrochemically inactive inosine residues to replace guanine, but still enable complementary base pairing. This technique has been rarely used, can only be applied to miRNA sequences naturally containing guanine residues, but has advantages in that it minimises sample pre-processing steps. Once hybridised to the capture probes, guanine residues from the target miRNA can undergo an up-to four electron oxidation which can lead to multiple products.<sup>48,49</sup> Guanine oxidation is considered chemically irreversible, with no corresponding reduction peaks appearing on a voltammogram. For this reason, any biosensor using guanine oxidation as a detection method, will rely on a single measurement, and cannot average out multiple voltammetric scans. Guanine oxidation also gives an upper limit of the potential window that most microRNA biosensors must use.

### Electroactive intercalators

Intercalators are molecules that bind to double-stranded oligonucleotides by inserting themselves in between base-pairs. They form stable, non-covalent pi-stacking interactions, and hence typically have large aromatic ring structures. Although they have most traditionally been used to stain and optically detect DNA, there exist several electrochemically active DNA intercalators, including oracet blue, methylene blue and the structurally similar toluidine blue, which have been used as redox reporters in microRNA sensing.<sup>50–54</sup> Typically, hybridisation of the target microRNA to a complementary capture probe immobilised at the electrode surface creates a DNA–RNA heteroduplex that is recognised by the electroactive intercalator which can then be oxidised or reduced.

An inverse take on this idea was adopted by Hou *et al.*<sup>55</sup> Complementary binding was used to keep methylene blue away from the electrode, instead of concentrating it at the electrode. The complementary DNA was not immobilised, but rather kept in solution and the bound methylene blue resulted in a much lower diffusion current to the electrode. This effect was increased by a hybridisation chain reaction which resulted in long double-stranded and G-quadruplex sequences forming because of the microRNA being present.



Fig. 2 Schematic representation of a sandwich sensor.

## Backbone binding molecules

Ruthenium(II) hexamine is a redox active molecule that has been shown to bind DNA and RNA through complexing to their phosphate backbone.<sup>41,56</sup> Improved electrochemical signal has been shown for ruthenium(II) hexamine on a DNA modified electrode compared to unmodified, which has been attributed to a facilitated diffusion mechanism, distinct from intercalator behaviour. Little work has been done to exploit this behaviour for sensing. Islam *et al.* employed ruthenium(III) hexamine backbone binding as part of a larger sensing strategy with multiple chemical amplification steps.<sup>57</sup> Ruthenium(III) was reduced to ruthenium(II) as it complexed microRNA at gold-loaded superparamagnetic iron oxide nanocubes. This system was coupled with ferricyanide which is reduced by the ruthenium(II). This leads to amplification of the signal as it cycles between the ruthenium(II) and ruthenium(III) oxidation states and continuous reduction of the reagent ferricyanide. A similar redox reporting strategy was employed by Su *et al.*<sup>24</sup> Two partial complementary sequences ensure coupling of Au-nanoparticle (NPs) decorated MoS<sub>2</sub> to a glassy carbon electrode. This recognition event is transduced by impedance spectroscopy of ferri/ferrocyanide and differential pulse voltammetry of intercalated ruthenium(III) hexamine.

## Enzyme modification

Enzyme based biosensors are perhaps the oldest and most well studied type of biosensors. There are numerous books and reviews discussing them in depth.<sup>58–61</sup> From the perspective of microRNA detection, enzymes are employed to catalytically generate and amplify the electrochemical signal. The easiest way to do this is *via* a sandwich sensor involving an immobilised capture probe and a secondary probe conjugated to an enzyme, either directly or indirectly, *via* a biotin–streptavidin interaction which occurs after the molecular recognition event.<sup>62–73</sup> Enzymes typically used are the same found in ELISAs and include horseradish peroxidase (HRP), alkaline phosphatase, and glucose oxidase.<sup>74–76</sup> Such enzymes are well studied, cheap and exhibit predictable behaviour. Depending on the nature of the enzyme, detection can originate from the product of the catalysis or the regeneration of the enzyme. Each microRNA can now be responsible for the generation of many signal molecules which depends on the catalytic turnover of the enzyme and the concentration of bound analyte.

A straightforward improvement to this can be *via* increasing the number of enzymes bound per microRNA molecule. As will be discussed later in this review, this can be achieved *via* various DNA constructs and nanoparticles. Commercially available polymers of horseradish peroxidase (polyHRP) can be conjugated instead of using a single enzyme.<sup>62</sup> Alternative conjugation techniques can also be used. Ma *et al.* used a polymerase-based pre-amplification step which replaced the microRNA signal with a DNA signal, to detect microRNAs in breast cancer cells.<sup>77</sup> The cytosine residues used had further been functionalised with biotin which, in a subsequent step,

became conjugated with a streptavidin bound alkaline phosphatase and generated the signal. A similar technique was employed by Zhou *et al.* to detect microRNAs in rice seedlings, using poly-U polymerase and biotinylated UTP.<sup>78</sup> Both these techniques gave similar results in terms of limit of detection (9 and 7 fM, respectively) and were declared fit-for-purpose in each application.

An alternative technique used has been to assemble enzymes into a larger structure for detection. Enzyme spheres, as reported by Wu *et al.*, are nanoporous spheres of HRP coated in porous Pd.<sup>79</sup> These spheres showed high activity toward H<sub>2</sub>O<sub>2</sub> electrochemistry thus obviating the need for additional redox reporters. The spheres were then conjugated to amine-terminated DNA probes complementary to the miRNA target. A complex detection strategy used Pb<sup>2+</sup>-induced cleavage of the ternary Y structure and rolling circle amplification techniques to further increase the sensitivity of the sensor, reaching a limit of detection of 0.2 fM.

## DNAzymes

DNAzymes (or Deoxyribozymes) are single-stranded DNA aptamers that exhibit a catalytic activity.<sup>80–84</sup> Their sequences are discovered from SELEX type processes, through successive cycles of selection and enrichment cycles.<sup>85,86</sup> They can exhibit a broad range of catalytic activities that could theoretically be exploited for microRNA sensing. The most commonly exploited DNAzyme for microRNA detection is a heme-based G-quadruplex peroxidase<sup>87,88</sup> which reduces hydrogen peroxide into water in a similar way to HRP.

A common approach is to use DNAzymes directly for their catalytic ability.<sup>27,89,90</sup> The DNAzymes can be built into the signal probes without need for conjugation chemistries. When compared to traditional peptide-based enzymes, DNAzymes offer the advantage of greater thermal and functional stability. Other biosensors have taken advantage of the ability to change DNA conformation to create a switch in their design.<sup>91–94</sup> The general principle is quite simple. The DNA is blocked by a complementary sequence from folding into its G-quadruplex functional structure. The presence of the microRNA causes a strand displacement which enables the DNAzyme to fold into its active conformation. The heme groups necessary for function are also added to the solution and so the DNAzyme can function only when the microRNA is present. This is a typical example of a strand displacement reaction being used for microRNA detection, which will be discussed in more general terms later in this review.

## Blocking electrode and polymer deposition

An alternative to having the miRNA binding event creating a detectable signal, is for this interaction to change the nature of the detector (Fig. 3).<sup>23–29,88,95–100</sup> Two similar but distinct



**Fig. 3** Principle of an impedance-based polymer film biosensor. (a) In absence of microRNA target, the electrode can easily detect reporter molecules. (b) Complementary binding brings a negative charge to the surface. (c) Polymer deposition inhibits charge transfer.

methods can be identified here: (i) directly blocking the electrode with microRNA, and (ii) using microRNA binding to guide deposition of an insulating polymer. Directly blocking the electrode relies on miRNA binding leading to a large change in electron transfer kinetics. Hence, the lowest limit of detection in this technique have been achieved by Labib *et al.* by enabling complementary binding to bring the protein streptavidin to the surface, through interactions with biotin.<sup>96</sup> However, Yammouri *et al.* recently demonstrated that complementary binding alone was able to induce a detectable impedance signal, but only with comparatively high concentrations in the nano- to micro-molar range.<sup>26</sup> Magnetic beads have also been used to amplify the signal, or pre-concentrate selected microRNAs at the electrode surface.<sup>23,99,100</sup> Nucleases are also commonly used in these detection methods to amplify and invert the signal.<sup>23,25,97</sup> Such enzymatic methods will be discussed in more detail later in this review.

Selectively depositing polymers on electrodes for microRNA detection has been explored with coulometric and impedance-based biosensors.<sup>26,95</sup> In a typical example, miRNA hybridisation to a complementary probe immobilised at the surface of an electrode creates a negatively charged surface that is subsequently used to guide the deposition of a positively charged, electrically insulating polymer. The net result of this process is a decrease in the efficacy of the electrode, measured by an increase in electrochemical impedance. A key to sensitivity in this technique is to use a charge-neutral capture probe. For this reason, Phosphorodiamidate Morpholino Oligomer (PMO) and Peptide Nucleic Acid (PNA) probes are typically preferred to standard, negatively charged, oligonucleotides.

Peng and Gao initially used a variation of this technique, by pre-tagging a microRNA with Ruthenium oxide nanoparticles.<sup>29</sup> The nanoparticles were then used to catalyse the polymerisation and deposition of a benzidine onto the electrodes. This avoided the need to catalyse the polymerisation separately and avoided the need for charge-neutral capture probes. A downside of this technique was the multi-step preparation of microRNA samples, using extraction kits, followed by a three-step process to attach the nanoparticles. This did, however, act as a good proof-of-concept for these types of microRNA sensors. Ding *et al.* used a similar concept, although using DNA enzymes to catalyse polyaniline deposition.<sup>88</sup> This was used in combination with HCR amplifica-

tion, and will be discussed later in this review. Optimisation of the preparation steps, ideally into a one-pot system would be ideal for taking these ideas forward.

## Nanoparticles

The use of nanoparticles and nanomaterials in biosensing in general has been extensively reviewed elsewhere, and theoretical models of such systems with regards to electrochemistry have already been thoroughly mathematically described.<sup>101–104</sup> Nanoparticles are multifunctional and for electrochemical sensing applications, we have separated them into five categories based on their mode of action: (i) increasing the electrode surface area, (ii) acting directly as a redox couple (iii) acting indirectly through catalysis (iv) acting indirectly by attaching to multiple redox couples or enzymes, and (v) acting to concentrate samples.

The effect of increasing the surface area of an electrode is reasonably straightforward. The exact nature of the surface is dependent on the size and distribution of nanoparticles across it. The change in surface geometry will change the diffusion and bulk transport properties to it, therefore altering the signal. This change may be unimportant when dealing with immobilised species. It is however worth noting that surface area scale differently according to the physico-chemical process: diffusion scales linearly as  $(2Dt)^{1/2}$  where  $D$  is the diffusion coefficient (typically  $10^{-10} \text{ m}^2 \text{ s}^{-1}$  for small aqueous species) which implies that asperities (roughness) smaller than 1–10  $\mu\text{m}$  will not affect diffusion limited currents in typical electrochemistry set-ups. In the short time domain however, the presence of the nanoparticles can lead to thin film behaviour and further complicate analysis. The length scale for electrostatic phenomena is the Debye length, which for physiological ionic strength is many orders of magnitude below the diffusional length scale, typically 0.5 nm. Techniques exploiting this are commonly used.

Through direct action as redox active species, nanoparticles or nanoclusters can generate a higher signal than their unimolecular counterparts by having more redox active atoms and delivering a higher effective concentration to the electrode surface. Silver nanoparticle (or nanostructure) reduction or oxidation has been used as a signal transducer.<sup>105</sup> Nanoparticles can be synthesised onto DNA probes, however Yang *et al.* used a DNA-templated nanoparticle synthesis as part of their detection mechanism.<sup>106</sup> Other nanoparticles can be used for a similar effect. Wang *et al.* precipitated copper nanoclusters onto their sensor then re-solubilised the copper to be re-detected by differential pulse stripping voltammetry.<sup>107</sup>

The innate catalytic activity of certain nanoparticles is not to be ignored. Silver and platinum nanoparticles have been used for their ability to catalyse hydrogen peroxide reduction,<sup>107,108</sup> similar to the Pd nanospheres with HRP scheme employed by Wu *et al.*, *vide supra*.<sup>79</sup> By allowing complementary binding to bring these to an electrode, this reduction can be quantified. Other catalytic activities have also

been studied.<sup>109,110</sup> Yu *et al.* used cobalt iron oxide ( $\text{CoFe}_2\text{O}_4$ ) nanoparticles functionalised onto a DNA probe, in a sandwich type sensor, to catalyse the reduction of terbium. The re-oxidation could then be used to indicate microRNA concentration. Wang *et al.* used copper metal organic frameworks modified onto gold nanoparticles to catalyse glucose oxidation.<sup>110</sup> The catalysis idea does not always have to give direct product detection. As discussed earlier, Peng and Gao flipped the idea by using ruthenium oxide nanoparticles to catalyse the polymerisation of 3,3' dimethoxy benzidine as a blocking film above their electrode.<sup>29</sup> This required pre-tagging their microRNA with ruthenium oxide labelled with a complementary short sequence and using a capture probe to selectively keep it at the electrode surface. The target miRNA effectively templates the deposition of an insulating film when the monomer solution and oxidant are added. The progress of the reaction and thus the degree of templating was followed using impedance spectroscopy in a solution of  $\text{Ru(II)}(\text{NH}_3)^{3+}$ . Interestingly, charge transfer resistance for this outer sphere probe was affected. Incubation times were lengthy at 60 min, but good LODs of  $\sim 3$  fM for their target miRNA were achieved.

Nanoparticles can also be used to bring complementary binding and transducer elements together. A single nanoparticle can host complementary binding probe, as well as redox active reporters. Ferrocene capped gold nanoparticles conjugated with streptavidin have been used and will assemble onto a biotinylated probe.<sup>111,112</sup> Similarly, other redox active molecules, including (but not limited to) dopamine, thionine, and ferrocene, have been immobilised onto nanoparticles for the purposes of creating a large signal from a single microRNA binding event.<sup>111–117</sup>

Magnetic micro- or nanoparticles can be used to pre-concentrate microRNA from the samples.<sup>23,43,57,99,100,111,118,119</sup> Strictly speaking, most magnetic beads used in device have micrometer scale, and so do not fit the IUPAC definition of nanoparticles (dimensions 1–100 nm).<sup>120</sup> Some devices however, use nano-scale magnetic beads for the same purposes.<sup>109,121</sup> Magnetic beads are particles that can be influenced by a magnetic field.<sup>122–124</sup> These tend to be ferromagnetic iron oxide, often coated in polystyrene. The magnetic beads are added to a biological sample, given time for the microRNA to hybridise, and then removed with a magnet. Then, typically one of two options are taken: heating the sample to remove the microRNA from the capture sequence, or using a magnetic electrode, to concentrate the magnetic beads at the surface. The former option is simply just a purification technique, while the latter is somewhat more creative and has the benefit of being isothermal. Alternatively, Ma *et al.* made use of a strand displacing polymerase to remove the microRNA from the magnetic beads.<sup>77</sup> This was just part of a more complicated mechanism, which resulted in modification of the magnetic beads with alkaline phosphatase, which then generated an electrochemical signal through its action on 2-phospho-L-ascorbic acid. In general, magnetic beads offer an easy, effective option for sample preparation and miRNA separation. If developing a biosensor for a laboratory setting, these

methods are clearly effective. Further automation of this technique would be required for developing it into point of care devices, and successfully doing so could create very powerful biosensors.

## Other nano-structures


Further to nanoparticles, other nano-structures have been exploited in the formation of biosensors. Nano-structure is a very broad term, and rightfully applies to most of the content of this review. This section therefore focuses on molecular methods that would otherwise go without description.

### DNA tetrahedra

DNA tetrahedra are self-assembling DNA nanostructures. They have been widely used in biosensing for their ability to give surface control.<sup>62,64,66,90,125–128</sup> They are assembled from four sequences of 55 nucleotides in one step.<sup>129</sup> Each of the four sequences creates the edges to one of the four faces, through complementary binding to the three other structures. The range of potential biological applications for these structures has been well reviewed.<sup>130</sup> The most common design for DNA tetrahedral based biosensors was suggested by Mitchell *et al.*<sup>131,132</sup> They are typically immobilised face down onto a gold electrode *via* three thiol groups, with the upward facing vertex carrying the probe of interest.<sup>132</sup> This controls the spread of this probe across the surface, causing an ordered and well defined spacing of 4 nm. Each probe is well anchored with three Au–thiol bonds, conveying approximately 5000 times as much stability as a single bond.<sup>131</sup> The tetrahedra can also help prevent electrode fouling through blocking non-specific protein absorption. Through this, DNA tetrahedra based biosensors are less likely to fail than those with less surface control. Further development using this, or other surface controlling methods, are likely to result in more clinically successful biosensors.

### Mesoporous silica

Several recent studies have been using mesoporous silica as a novel method to detect miRNA (Fig. 4).<sup>21,22,133,134</sup> The concept involves entrapping an electroactive reporter molecule within these nanoparticles and blocking their exit with single



**Fig. 4** Mechanism of miRNA detection using mesoporous silica. (a) Mesoporous silica is loaded with electroactive signalling molecules. (b) The pores of the silica are capped with miRNA capture probes. (c) Complementary binding leads to dissociation from the pores. (d) The electroactive molecules escape the silica to be detected on an electrode.

stranded capture probes. The capture probes are typically made of DNA and bind to the mesoporous silica due to a positive zeta potential on the nanoparticles. Upon complementary binding with target miRNA, the capture probes dissociate from the silica, causing the entrapped signal molecule to escape the silica. This allows a potentially massive signal amplification, and the choice of an ideal molecule to detect. Gai *et al.* entrapped ferricyanide particles, initially for a ratiometric sensor, comparing the DPV signal to Ruthenium hexamine in solution.<sup>133</sup> This work was later expanded upon, to create a similar potentiometric sensor, comparing the ease of ferricyanide reduction at a cathode, to an glucose oxidase modified anode.<sup>21</sup> Similar work was carried out by Deng *et al.*, by entrapping glucose within the mesoporous silica, and detecting it using a portable personal glucometer.<sup>22</sup> This work creates a great proof of concept for a portable microRNA biosensor. However, glucose as a signalling molecule will likely be unviable in patient samples, due to the high levels already present in blood, and false positives coming from diabetic patients.

## Other useful techniques

Often, sensing strategies are used with a myriad of other useful techniques, designed to increase sensitivity, amplify the signal, or aid in separation from the biological matrix. These techniques create additional complexity in the biosensor design, and often work in close synergy with the detection scheme. It becomes difficult to assess the relative merits of a technique, as they are rarely used in isolation. The following section discusses some of the more common techniques used.

### Signal amplification through polymerases

Polymerases are well known enzymes which catalyse the formation of DNA strands and were made famous by polymerase chain reaction which revolutionised molecular biology.<sup>135</sup> These useful enzymes are often implemented into microRNA biosensors as a signal amplifier. Many biosensors use microRNA as a primer for DNA polymerase, which alongside a nuclease or strand displacement causes a large amount of a signalling sequence to be formed.<sup>54,92,94,106,118,127</sup> Rolling circle amplification (RCA) is a particular example of this, which uses a circular DNA (or RNA) as a template molecule.<sup>136</sup> The polymerase processes around the template molecule multiple times, creating tandem repeats of complementary sequences (Fig. 5). Unlike traditional PCR-based methods, RCA is isothermal and one-step. The length of the amplification is dependent on the number of free nucleotides present for the polymerase to use. In microRNA sensing, RCA is most commonly used in combination with other detection methods as a signal amplifier.<sup>79,109,127,137</sup> Typically, the miRNA allows an initial primer to bind for the amplification to occur. The tandem repeats resulting from the amplification allow multiple signalling molecules to bind. The value of RCA arises from this ability to isothermally amplify a signal.



**Fig. 5** General principle of rolling circle amplification (RCA). (a) Target complementary binds to circular template. (b) The polymerase uses target sequence as a primer. (c) The polymerase displaces the target as it processes around the template. (d) The result is tandem repeats of the target sequence with a designed secondary sequence.

Template-independent polymerases have also been used to amplify microRNA signals.<sup>78,99</sup> As the name suggests, template-independent polymerases, can catalyse the addition of nucleotides to DNA or RNA without a template sequence to copy. Typically adding string of a single nucleotide. As described earlier, Zhou *et al.* made use of poly(U)polymerase in combination with biotinylated uracil residues for detection.<sup>78</sup> Koo *et al.* alternatively used poly(A)polymerase to allow the pre-concentrated target microRNA to adsorb to an electrode, hindering electron transfer.<sup>99</sup> In both cases, the polymerases are acting as signal amplifiers enabling transduction. The isothermal amplification of polymerase techniques is powerful; however, it comes at a need for additional reagents within the sample, chiefly nucleotide triphosphates.

### Use of nucleases

Specific nucleases have been used in miRNA sensors, as part of signal transduction or amplification. Duplex Specific Nucleases (DSN) are enzymes that can specifically recognise duplex DNA or DNA:RNA hybrids.<sup>138</sup> Only the DNA component of the duplex is then hydrolysed, allowing RNA to dissociate from the enzyme. This unique specificity allows these enzymes to be used in microRNA biosensors, acting as an isothermal signal amplifier. DSN has lent itself readily to impedance-based biosensors.<sup>23,25</sup> An electrode is functionalised with a DNA capture probe. When the complementary microRNA binds, the DSN will selectively cleave the DNA, allowing a redox reporter to get closer to the electrode, thus reducing the resistance to electron transfer (Fig. 6). An alternative mechanism has been used to remove reporter molecules which are tagged onto the immobilised DNA capture sequence.<sup>139</sup> The action of this enzyme leaves a 3' hydroxyl at the electrode surface, which can also be exploited for further chemical or enzymatic reactions.<sup>54</sup> A novel use of DSN was proposed by Castaneda *et al.*<sup>140</sup> using platinum nanoparticles functionalised with DNA capture probes. MiRNA binding allowed DSN to remove the DNA from the nanoparticles, which could then impact an ultramicroelectrode, and catalyse hydrazine reduction.



**Fig. 6** The use of duplex specific nuclease in biosensing. (a) Electron transfer is hindered by a surface concentration of capture probes. (b) Complementary binding of the target sequence allows duplex specific nuclease to selectively remove capture probes. (c) Electron transfer is easier as a result.

### Strand displacement reactions

Strand displacement reactions (SDR) and Toehold Mediated Strand Displacement Reactions (TMSDR) are a growing area in nanotechnology.<sup>48,141,142</sup> They have already been used to create logic gates, catalysis, and nanomachines. The principle is summarised in Fig. 7. Using DNA sequences containing overhangs, a new initiator strand which has more complementary bases to one of the bound strands can displace another. The exact combination of effects can be carefully tweaked, and advanced mechanisms can be set up from this principle. One strand displacement can lead to another strand displacement, allowing a recycling of the initiator strand. A typical use of this mechanism in biosensing would be to have the microRNA as an initiator and to detect one of the displaced strands.

A novel and complicated take on this mechanism was used by Zhang *et al.*<sup>14</sup> Here a strand displacement reaction, caused by microRNA-binding released a “DNA Walker” sequence. This DNA walker then bound to a complementary DNA hairpin on the electrode surface, causing a stem loop to open. It was then displaced by another hairpin structure which was functionalised with ferrocene. This recycled the walker for further binding. The electrochemical oxidation of the ferrocene was then detected by DPV. The whole system was considered regenerable through heating. Stem-loops are hairpin shaped DNA secondary structures commonly used in DNA sensing, and their opening is an intramolecular case of a strand displacement reaction. They have a large single-stranded loop of DNA, generally with a short self-complementary stem. Oligonucleotides complementary to the loop and one of the stem sequences can therefore cause the loop to open upon binding. The stem-loop opening has been traditionally used in



**Fig. 7** Principle of a strand displacement reaction. In the presence of a “toehold” sequence, a longer complementary sequence will displace a shorter sequence.

molecular beacon technology, where each end of the stem loop is functionalised, such that a quenched fluorescence is enabled upon binding to oligonucleotides. This creates a highly sequence specific sensing. The applications in electrochemistry can be quite different. In all examples found, the stem loops are immobilised onto an electrode. The similar DNA architecture can be exploited in different ways that we categorised into functionalised stem loops and non-functionalised stem loops.

Most commonly, stem loops are functionalised with biotin. When closed, the biotin is held close to the electrode and inaccessible to binding with streptavidin. Binding with complementary sequences, causes the hairpin to open and streptavidin to bind to the now accessible biotin. Signal transduction is then achieved through whatever streptavidin is bound to. Stem loops can also be functionalised with electroactive species. However, this is not enough to give signal transduction. Yang *et al.* used this idea with a nuclease: complementary binding caused stem loop opening, causing the electroactive moiety to be removed from the electrode. They multiplexed this by using ferrocene and methylene blue on separate stem loops with different sequences.<sup>139</sup> Another strategy was used by Liu *et al.* where the ferrocene bound stem loop was held away from the electrode by using rigid DNA tetrahedral nanostructures. Complementary binding enabled stem loop opening, allowing enough flexibility for the ferrocene to reach the electrode, thus generating the detectable signal.<sup>125</sup>

Non-functionalised probes typically allow signal transduction through a secondary sequence binding.<sup>73</sup> The opened stem-loop leaves either part of the microRNA or part of itself single stranded, allowing complementary binding of this second sequence. These secondary sequences can be functionalised to generate a signal in many ways as previously described. The stem loop therefore offers greater freedom in sequence design than a single-stranded probe. This freedom of design was exploited by Meng *et al.*<sup>93</sup> Upon complementary binding and stem loop opening, there was a leftover single stranded section of the probe. This was designed to form a G-quadruplex structure, in the presence of potassium, and the addition of a hemin group allowed this quadruplex to become a DNAzyme, which in turn enabled oxidation of hydrogen peroxide.

Hybridisation chain reaction (HCR) is a popular case of strand displacement reaction used to amplify a signal.<sup>88,110,137,143–146</sup> A single-stranded initiator sequence is placed amongst two hairpin sequences. The initiator (microRNA signal) causes the opening of the first hairpin, which opens the second, which in turn opens another copy of the first. This causes a cascade reaction, and enzyme-free amplification of the DNA. This can be converted into an electrochemical signal. The simplest way to do so is to modify the hairpins. This has been achieved with biotin, allowing a streptavidin bound enzyme to signal.<sup>64</sup> Alternatively, the use of nanoparticles or other attached molecules is also possible.<sup>55,106,107</sup> Hairpins can also be designed to leave single-stranded sections after HCR. New auxiliary probes, conjugated

Table 1 Summary of detection types

| Detection method                  | LOD (M)               | Dynamic range                            | Biological sample                  | Techniques used                                                                               | Ref. |
|-----------------------------------|-----------------------|------------------------------------------|------------------------------------|-----------------------------------------------------------------------------------------------|------|
| <b>Backbone binding</b>           |                       |                                          |                                    |                                                                                               |      |
| DPV                               | $1 \times 10^{-16}$   | 100 aM to 100 pM                         | Serum                              | Stem loop opening                                                                             | 151  |
| Coulometric                       | $1 \times 10^{-16}$   | 100 aM to 1 nM                           | RNA extracts                       | DNA concatemers<br>Magnetic beads                                                             | 57   |
| DPV                               | $7.8 \times 10^{-16}$ | 10 fM to 1 nM                            | Spiked serum                       | Nanoparticles<br>Nanostructure formation<br>Two detection methods                             | 24   |
| <b>Blocking electrode surface</b> |                       |                                          |                                    |                                                                                               |      |
| SWV                               | $2 \times 10^{-18}$   | 10 aM to 1 fM                            | Serum                              | Four-way junction                                                                             | 96   |
| SWV                               | $5 \times 10^{-18}$   | 10 aM to 1 $\mu$ M                       | Serum                              | Four-way junction                                                                             | 152  |
| EIS                               | $6 \times 10^{-17}$   | 0.5 fM to 40 fM                          | Serum                              | Enzyme<br>Magnetic beads<br>Nuclease                                                          | 23   |
| DPV                               | $1.7 \times 10^{-16}$ | 0.5 to 100 fM                            | RNA extract                        | Nuclease                                                                                      | 97   |
| EIS                               | $4.5 \times 10^{-16}$ | 10 fM to 1 nM                            | Spiked serum                       | Nanostructure formation<br>Two methods of detection                                           | 24   |
| EIS                               | $1 \times 10^{-15}$   | 2 fM to 2 pM                             | RNA extracts and serum             | Nuclease                                                                                      | 25   |
| SWV                               | $8 \times 10^{-15}$   | 1 fM to 1 nM                             | —                                  | Antibody based removal                                                                        | 98   |
| DPV                               | $1 \times 10^{-14}$   | 5 fM to 5 pM                             | RNA extracts                       | Magnetic beads<br>Poly(A)polymerase                                                           | 99   |
| Coulometric                       | $2 \times 10^{-14}$   | 10 fM to 10 nM                           | Urine                              | —                                                                                             | 95   |
| EIS                               | $7 \times 10^{-13}$   | 1 pM to 100 pM                           | RNA extracts                       | —                                                                                             | 31   |
| DPV                               | $1 \times 10^{-12}$   | 1 pM to 10 nM                            | RNA extracted from<br>exosomes     | Magnetic beads                                                                                | 100  |
| EIS                               | $1 \times 10^{-11}$   | 80 nM to 150 $\mu$ M                     | Serum                              | —                                                                                             | 26   |
| <b>DNA enzyme</b>                 |                       |                                          |                                    |                                                                                               |      |
| CA                                | $5 \times 10^{-19}$   | 1 aM to 100 pM                           | None                               | Polymerase and endonuclease<br>cascade reaction                                               | 92   |
| DPV                               | $1.2 \times 10^{-15}$ | 10 fM to 1 nM                            | Cell lysates                       | Strand displacement reaction                                                                  | 91   |
| DPV                               | $2.0 \times 10^{-15}$ | 1 nM to 10 fM                            | Spiked serum                       | Junction probes<br>Nanostructure formation<br>Nanoparticles<br>DNA tetrahedra                 | 90   |
| DPV                               | $5.4 \times 10^{-15}$ | 20 fM to 50 pM                           | RNA extracts                       | Polymerase                                                                                    | 94   |
| DPV                               | $6 \times 10^{-15}$   | 0.01 to 500 pM                           | RNA extract                        | Nanoparticles<br>Stem loop opening<br>Nanostructure formation<br>Strand displacement reaction | 93   |
| SWV                               | $5.2 \times 10^{-12}$ | 0.01 nM to 1 $\mu$ M                     | Spiked serum                       | Strand displacement reaction                                                                  | 89   |
| <b>Enzyme</b>                     |                       |                                          |                                    |                                                                                               |      |
| CA                                | $2.2 \times 10^{-19}$ | 1 aM to 10 fM                            | Spiked saliva                      | Magnetic beads<br>Junction probes                                                             | 119  |
| CA                                | $5 \times 10^{-18}$   | “Approximately 5 orders of<br>magnitude” | RNA extracts                       | Junction probes                                                                               | 153  |
| CA                                | $1 \times 10^{-17}$   | 10 aM to 1 pM                            | None                               | DNA tetrahedra<br>Hybridisation chain reaction                                                | 64   |
| CA                                | $1.4 \times 10^{-16}$ | 1 fM to 100 pM                           | Spiked serum                       | Nanoparticles                                                                                 | 63   |
| DPV                               | $1.6 \times 10^{-16}$ | 0.1 fM to 0.1 nM                         | Diluted serum                      | Nanoparticles<br>Stem loop opening<br>Strand displacement reaction                            | 73   |
| DPV                               | $2 \times 10^{-16}$   | 3 fM to 1 nM                             | None                               | Nanoparticles<br>Stem loop opening<br>Junction probes<br>Rolling circle amplification         | 79   |
| CA                                | $2 \times 10^{-16}$   | 0.5 fM to 1 pM                           | Serum                              | Stem loop opening                                                                             | 68   |
| DPV                               | $3.5 \times 10^{-16}$ | 1 fM to 10 nM                            | Spiked serum                       | Stem loop opening<br>Strand displacement reaction                                             | 110  |
| CV                                | $1 \times 10^{-15}$   | “6 orders of magnitude”                  | None                               | Nanoparticles<br>DNA tetrahedra                                                               | 66   |
| DPV                               | $1.7 \times 10^{-15}$ | 10 fM to 1000 fM                         | RNA extract from rice<br>seedlings | Stem loop opening<br>Poly(U) polymerase                                                       | 78   |
| CA                                | $3 \times 10^{-15}$   | 10 fM to 5 pM                            | None                               | Nanoparticles<br>Labelling microRNA                                                           | 154  |
| DPV                               | $3.6 \times 10^{-15}$ | 10 fM to 0.1 nM                          | Cell lysates                       | Nanoparticles                                                                                 | 67   |
| CA                                | $4 \times 10^{-15}$   | 8 fM to 10 pM                            | RNA extracts                       | Stem loop opening<br>Stem loop opening                                                        | 76   |

Table 1 (Contd.)

| Detection method                              | LOD (M)               | Dynamic range                    | Biological sample              | Techniques used                                                                        | Ref. |
|-----------------------------------------------|-----------------------|----------------------------------|--------------------------------|----------------------------------------------------------------------------------------|------|
| CA                                            | $6 \times 10^{-15}$   | 0.01 pM to 7 pM                  | RNA extracts                   | Stem loop opening<br>Nanoparticles                                                     | 71   |
| DPV                                           | $9 \times 10^{-15}$   | 10 fM to 10 nM                   | RNA extracts                   | Nanostructure formation<br>Polymerase recycling<br>Stem loop opening<br>Magnetic beads | 155  |
| CA                                            | $1 \times 10^{-14}$   | 20 fM to 10 pM                   | RNA extracts                   | Nuclease                                                                               | 69   |
| CA                                            | $1 \times 10^{-14}$   | 10 fM to 1 nM                    | Serum                          | DNA tetrahedra                                                                         | 62   |
| DPV                                           | $2.5 \times 10^{-13}$ | 0.5 pM to 12.5 nM                | RNA extract                    | Strand displacement<br>Rolling circle amplification                                    | 137  |
| EIS                                           | $4 \times 10^{-13}$   | 1.7 pM to 900 pM                 | Diluted, spiked serum          | Pre-labelled miRNA<br>Liposomes                                                        | 156  |
| CA                                            | $6 \times 10^{-13}$   | 0.6 pM to 20 nM                  | RNA extract, serum             | Strand displacement reaction                                                           | 147  |
| DPV                                           | $6 \times 10^{-13}$   | 1 pM to 25 nM                    | Diluted RNA extracts           | Strand displacement reaction                                                           | 157  |
| CA                                            | $1 \times 10^{-12}$   | 1 pM to 1 nM                     | RNA extracts                   | —                                                                                      | 65   |
| Pulse voltammetry                             | $2 \times 10^{-12}$   | 2 pM to 200 nM                   | RNA extracts                   | —                                                                                      | 158  |
| CA                                            | $7 \times 10^{-12}$   | 7 pM to 2.5 nM                   | RNA extracts                   | Magnetic beads                                                                         | 74   |
| CA                                            | $1.1 \times 10^{-11}$ | 100 pM to 100 nM                 | 10% serum                      | Stem loop opening<br>Secondary structure change                                        | 159  |
| CA                                            | $4 \times 10^{-11}$   | 0.14 to 100 nM                   | RNA extracts                   | Magnetic beads                                                                         | 75   |
| DPV                                           | $1 \times 10^{-7}$    | —                                | RNA extracts                   | Attaching RNA to electrode                                                             | 70   |
| DPV                                           | $1.6 \times 10^{-7}$  | —                                | RNA extracts                   | RNA specific protein                                                                   | 160  |
| CV integrating peaks                          | —                     | —                                | Serum                          | Stem loop opening<br>Four-way junction<br>Nanoparticles                                | 161  |
| DPV                                           | $6 \times 10^{-17}$   | 0.1 fM to 100 pM                 | Serum                          | —                                                                                      | 72   |
| <b>Inorganic catalyst labelled</b>            |                       |                                  |                                |                                                                                        |      |
| CA                                            | $2 \times 10^{-13}$   | 0.5 pM to 400 pM                 | RNA extracts                   | Pre-labelled microRNA                                                                  | 44   |
| <b>Guanine oxidation</b>                      |                       |                                  |                                |                                                                                        |      |
| DPV                                           | $1 \times 10^{-12}$   | 1 pM to 1 nM<br>1 nM to 10 nM    | None                           | Carbon nanotubes<br>(Two dynamic ranges reported)                                      | 46   |
| DPV                                           | $5 \times 10^{-9}$    | —                                | None                           | —                                                                                      | 45   |
| DPV                                           | $7 \times 10^{-7}$    | 1.4 $\mu$ M to 5.6 $\mu$ M       | None                           | —                                                                                      | 47   |
| <b>Intercalators</b>                          |                       |                                  |                                |                                                                                        |      |
| DPV                                           | $1.5 \times 10^{-17}$ | 50 aM to 50 pM                   | Spiked plasma                  | Nuclease<br>Polymerase                                                                 | 54   |
| DPV                                           | $3.3 \times 10^{-17}$ | 100 aM to 100 nM                 | Serum                          | Nanoparticles                                                                          | 53   |
| DPV                                           | $6 \times 10^{-16}$   | 2 fM to 8 pM                     | Plasma                         | Nanoparticles                                                                          | 51   |
| DPV                                           | $8.4 \times 10^{-14}$ | 0.1 to 500 pM                    | —                              | Carbon nanotubes                                                                       | 52   |
| DPV                                           | $5 \times 10^{-13}$   | 10 fM to 1 nM and 1 nM to 100 nM | None                           | Carbon nanotubes                                                                       | 50   |
| DPV                                           | $1 \times 10^{-12}$   | 1 pM to 800 pM                   | None                           | Hybridisation chain reaction                                                           | 55   |
| <b>Mesoporous silica</b>                      |                       |                                  |                                |                                                                                        |      |
| Potentiometric                                | $2.7 \times 10^{-18}$ | 10 aM to 1 pM                    | Serum                          | Nanoparticles                                                                          | 21   |
| DPV                                           | $3.8 \times 10^{-17}$ | 0.05 fM to 100 fM                | Tumour cells                   | —                                                                                      | 134  |
| Potentiometric                                | $1.9 \times 10^{-11}$ | 50 pM to 5 nM                    | Cell lysates                   | —                                                                                      | 22   |
| DPV                                           | $3.3 \times 10^{-17}$ | 0.1 fM to 1500 fM                | Cell lysates                   | —                                                                                      | 133  |
| <b>Nanoparticles as a direct redox couple</b> |                       |                                  |                                |                                                                                        |      |
| DPV                                           | $6.7 \times 10^{-14}$ | 10 nM to 100 pM                  | None                           | Stem loop opening                                                                      | 108  |
| LSV                                           | $2 \times 10^{-17}$   | 0.1 to 50 fM                     | Serum                          | Stem loop opening<br>Labelled miRNA                                                    | 162  |
| LSV                                           | $5 \times 10^{-17}$   | 1 fM to 10 pM                    | RNA extracts and serum samples | DNA tetrahedra<br>Rolling circle amplification                                         | 127  |
| LSV                                           | $4 \times 10^{-16}$   | 1 fM to 1 nM                     | Spiked serum                   | DNA tetrahedra<br>Stem loop opening<br>Polymerase                                      | 126  |
| DPV                                           | $6.4 \times 10^{-16}$ | 1 fM to 0.1 nM                   | Spiked serum                   | Polymerase<br>Hybridisation chain reaction                                             | 106  |
| DPV stripping voltammetry                     | $1 \times 10^{-17}$   | 0.1 fM to 10 pM                  | Spiked blood                   | Strand displacement reaction<br>Nuclease<br>Hybridisation chain reaction               | 107  |
| SWV                                           | $1.2 \times 10^{-14}$ | 50 fM to 30 pM                   | Spiked serum                   | Magnetic beads<br>Polymerase                                                           | 118  |

Table 1 (Contd.)

| Detection method                                | LOD (M)                                         | Dynamic range              | Biological sample                            | Techniques used              | Ref. |
|-------------------------------------------------|-------------------------------------------------|----------------------------|----------------------------------------------|------------------------------|------|
| <b>Nanofoam acting as a redox couple</b>        |                                                 |                            |                                              |                              |      |
| CV                                              | $2 \times 10^{-16}$                             | 0.2 fM to 1 nM             | Plasma with and without dilution and spiking | —                            | 105  |
| <b>Nanoparticles labelled with redox couple</b> |                                                 |                            |                                              |                              |      |
| SWV                                             | $7.6 \times 10^{-19}$                           | 1 aM to 10 pM              | Serum                                        | Nanoparticles                | 113  |
| DPV                                             | $1.1 \times 10^{-17}$                           | 0.1 fM to 100 pM           | Spiked serum                                 | Stem loop opening            | 115  |
|                                                 |                                                 |                            |                                              | Nuclease                     |      |
|                                                 |                                                 |                            |                                              | Hybridisation chain reaction |      |
| CV                                              | $1.4 \times 10^{-16}$                           | 5 fM to 100 fM             | Serum                                        | Magnetic beads               | 111  |
|                                                 |                                                 |                            |                                              | Stem loop opening            |      |
|                                                 |                                                 |                            |                                              | Nanoparticles                |      |
| DPV                                             | $4.4 \times 10^{-16}$ and $4.6 \times 10^{-16}$ | 1 fM to 1 nM               | Cell lysates                                 | Stem loop opening            | 115  |
|                                                 |                                                 |                            |                                              | Hybridisation chain reaction |      |
| SWV                                             | $8 \times 10^{-15}$                             | $10^{-15}$ to $10^{-10}$ M | Diluted serum                                | —                            | 116  |
| CV                                              | $1 \times 10^{-14}$                             | 10 fM to 2 pM              | Serum                                        | Pre-labelled microRNA        | 112  |
| DPV                                             | $4.5 \times 10^{-14}$                           | 0.1 to 10 pM               | None                                         | Pre-labelled microRNA        | 117  |
| <b>Nanoparticle (catalytic)</b>                 |                                                 |                            |                                              |                              |      |
| SWV                                             | $3 \times 10^{-16}$                             | 1 fM to 2 nM               | RNA extracts                                 | Magnetic beads               | 109  |
|                                                 |                                                 |                            |                                              | Rolling circle amplification |      |
| DPV                                             | $1.92 \times 10^{-15}$                          | 0.5 fM to 5 pM             | Cell lysates                                 | Stem loop opening            | 107  |
| CA                                              | $8 \times 10^{-14}$                             | 0.3 pM to 200 pM           | RNA extracts                                 | —                            | 163  |
| CV                                              | $1.87 \times 10^{-12}$                          | 5.6 pM to 560 nM           | Serum                                        | —                            | 164  |
| CA frequency analysis                           | $1 \times 10^{-10}$                             | 0.1 nM to 10 nM            | None                                         | Nuclease                     | 140  |
| <b>Nanoparticle (other)</b>                     |                                                 |                            |                                              |                              |      |
| CV                                              | $1.6 \times 10^{-14}$                           | 0.05 to 0.9 pM             | RNA extracts                                 | —                            | 165  |
| <b>Polymer deposition</b>                       |                                                 |                            |                                              |                              |      |
| EIS                                             | $5 \times 10^{-16}$                             | 1 fM to 5 pM               | RNA extracts                                 | DNA enzyme                   | 27   |
| DPV                                             | $5 \times 10^{-16}$                             | 1 fM to 100 pM             | Serum                                        | Stem loop opening            | 88   |
|                                                 |                                                 |                            |                                              | Hybridisation chain reaction |      |
| EIS                                             | $2 \times 10^{-15}$                             | 5 fM to 2 pM               | RNA extracts, and serum                      | —                            | 28   |
| EIS                                             | $3 \times 10^{-15}$                             | 6 fM to 2 pM               | RNA extracts                                 | pre-labelled microRNA        | 29   |
| EIS and DPV                                     | $1.7 \times 10^{-10}$                           | —                          | RNA extracts                                 | —                            | 30   |
| <b>Redox labelled</b>                           |                                                 |                            |                                              |                              |      |
| SWV                                             | $1 \times 10^{-17}$                             | 10 aM to 1 nM              | 50% diluted blood                            | Magnetic nanoparticles       | 121  |
|                                                 |                                                 |                            |                                              | Conformational changes       |      |
| SWV                                             | $3 \times 10^{-17}$                             | 100 aM to 1 nM             | Spiked serum                                 | Nuclease                     | 148  |
|                                                 |                                                 |                            |                                              | Junction probes              |      |
| DPV                                             | $6.7 \times 10^{-17}$                           | 0.1 to 100 fM              | RNA extract from exosomes                    | Magnetic beads               | 14   |
|                                                 |                                                 |                            |                                              | Strand displacement reaction |      |
|                                                 |                                                 |                            |                                              | Stem loop opening            |      |
| CV                                              | $5 \times 10^{-16}$                             | 1 fM to 50 fM              | —                                            | DNA flexibility              | 166  |
| SWV                                             | $1.4 \times 10^{-15}$                           | 5 fM to 500 pM             | Cell lysates                                 | Strand displacement reaction | 167  |
| SWV                                             | $4.2 \times 10^{-15}$                           | 5 fM to 50 pM              | Cell lysates                                 | Stem loop opening            | 139  |
|                                                 | $3 \times 10^{-15}$                             |                            |                                              | Nuclease                     |      |
|                                                 |                                                 |                            |                                              | (Two sequences detected)     |      |
| SWV                                             | $3 \times 10^{-14}$                             | 100 fM to 2 nM             | Tumour cells                                 | Strand displacement reaction | 42   |
| DPV                                             | $1 \times 10^{-13}$                             | 0.1 pM to 10 nM            | None                                         | Hybridisation chain reaction | 168  |
|                                                 |                                                 |                            |                                              | Dendrimer formation          |      |
| DPV                                             | $1 \times 10^{-11}$                             | 100 pM to 1 $\mu$ M        | Spiked cell lysis                            | DNA tetrahedra               | 125  |
|                                                 |                                                 |                            |                                              | Nanoparticles                |      |
|                                                 |                                                 |                            |                                              | Stem loop opening            |      |
| DPV                                             | $1 \times 10^{-8}$                              | 10 nM to 200 nM            | RNA extracts                                 | Magnetic beads               | 43   |

to signalling molecules can then be added to bind to these single-stranded sections.<sup>114,115</sup> A novel take on HCR, has recently been described by Zhang *et al.* that includes regeneration of the miRNA.<sup>147</sup> Techniques like this enable high levels of isothermal amplification, creating very sensitive systems.

SDR can create isothermal amplification and novel sensing mechanisms. There is a lot of potential for advanced logic

gates and data processing within these systems and it is highly likely that new variations on these methods will provide fascinating next generation biosensors.

### Junction probes

Novel Y-shaped junction probes have been used in a lot of miRNA sensing strategies.<sup>79,119,148</sup> These structures were

initially described in 2008 by Nakayama *et al.* as a method of isothermally amplifying sample signals<sup>149</sup> through use of an oligonucleotide 3-way junction involving two detection probes instead of one. In this strategy, the detection probes cannot complementary bind to each other at room temperature. The signal probe can partially complementary bind to each of the probes, enabling the Y-shaped structure to form. This concept boasts high sequence specificity and mismatch detection because the formed structure is the result of three partially stable interactions. A proof of concept biosensor using this strategy was developed in 2009 to detect DNA.<sup>150</sup>

## Conclusions

Nucleic acid sensing is on the frontier of diagnostic medicine, with many diseases being linked to altered expression of specific miRNA biomarkers. This creates a clinical need to develop effective microRNA biosensors for point of care testing. With modern day technology, many novel electrochemical biosensors are being developed, often exploiting unique and exciting molecular mechanisms (Table 1). Such mechanisms are not mutually exclusive and can work synergistically to improve the detection of microRNA. Most articles report on technologies incorporating a host of different ideas, and as such it can be challenging to identify the merits of any one component.

Unsurprisingly, with such new detection chemistries, the number of reports on clinical or other real-world samples remains modest. Evaluation under realistic diagnostic conditions will yield valuable information of the development of these technologies.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

PG acknowledges support from a BBSRC PhD scholarship, SL and DOH acknowledge support from a CRUK grant (C49996/A26141). We also thank Dr Robert Channon for proofreading this paper.

## References

- 1 L. He and G. J. Hannon, *Nat. Rev. Genet.*, 2004, **5**, 522–531.
- 2 J. Wang, J. Chen and S. Sen, *J. Cell Physiol.*, 2016, **231**, 25–30.
- 3 M. Weiland, X. H. Gao, L. Zhou and Q. S. Mi, *RNA Biol.*, 2012, **9**, 850–859.
- 4 Y. S. Lee and A. Dutta, *Annu. Rev. Phytopathol.*, 2009, **4**, 199–227.
- 5 S. Mi, J. Zhang, W. Zhang and R. S. Huang, *Microna*, 2013, **2**, 63–71.
- 6 R. E. Drury, D. O'Connor and A. J. Pollard, *Front. Immunol.*, 2017, **8**, 1182.
- 7 G. Iacomino and A. Siani, *Genes Nutr.*, 2017, **12**, 23.
- 8 L. Maegdefessel, *J. Intern. Med.*, 2014, **276**, 633–644.
- 9 O. Issler and A. Chen, *Nat. Rev. Neurosci.*, 2015, **16**, 201–212.
- 10 D. Sayed and M. Abdellatif, *Physiol. Rev.*, 2011, **91**, 827–887.
- 11 M. Nordberg, J. Duffus and D. M. Templeton, *Journal*, 2004, **76**, 1033.
- 12 V. Prasad, J. Lenzer and D. H. Newman, *Br. Med. J.*, 2016, **352**, h6080.
- 13 C. P. Price, *Br. Med. J.*, 2001, **322**, 1285–1288.
- 14 J. Zhang, L. L. Wang, M. F. Hou, Y. K. Xia, W. H. He, A. Yan, Y. P. Weng, L. P. Zeng and J. H. Chen, *Biosens. Bioelectron.*, 2017, **102**, 33–40.
- 15 R. Wang, L. Wang, X. Xu and W. Jiang, *Sens. Actuators, B*, 2018, **268**, 287–292.
- 16 J. S. Daniels and N. Pourmand, *Electroanalysis*, 2007, **19**, 1239–1257.
- 17 A. Chen and B. Shah, *Anal. Methods*, 2013, **5**, 2158–2173.
- 18 D. Grieshaber, R. MacKenzie, J. Vörös and E. Reimhult, *Sensors*, 2008, **8**, 1400–1458.
- 19 C. Batchelor-McAuley, E. Katelhon, E. O. Barnes, R. G. Compton, E. Laborda and A. Molina, *ChemistryOpen*, 2015, **4**, 224–260.
- 20 D. R. Thevenot, K. Tóth, R. A. Durst and G. S. Wilson, *Journal*, 1999, **71**, 2333.
- 21 P. Gai, C. Gu, T. Hou and F. Li, *ACS Appl. Mater. Interfaces*, 2018, **10**, 9325–9331.
- 22 K. Deng, Y. Zhang and X. Tong, *Anal. Bioanal. Chem.*, 2018, **410**, 1863–1871.
- 23 J. Zhang, D. Z. Wu, S. X. Cai, M. Chen, Y. K. Xia, F. Wu and J. H. Chen, *Biosens. Bioelectron.*, 2016, **75**, 452–457.
- 24 S. Su, W. Cao, W. Liu, Z. Lu, D. Zhu, J. Chao, L. Weng, L. Wang, C. Fan and L. Wang, *Biosens. Bioelectron.*, 2017, **94**, 552–559.
- 25 Y. Ren, H. Deng, W. Shen and Z. Gao, *Anal. Chem.*, 2013, **85**, 4784–4789.
- 26 G. Yammouri, J. Mandli, H. Mohammadi and A. Amine, *J. Electroanal. Chem.*, 2017, **806**, 75–81.
- 27 H. Deng, W. Shen, Y. Ren and Z. Gao, *Biosens. Bioelectron.*, 2014, **60**, 195–200.
- 28 Z. Gao, H. Deng, W. Shen and Y. Ren, *Anal. Chem.*, 2013, **85**, 1624–1630.
- 29 Y. Peng and Z. Gao, *Anal. Chem.*, 2011, **83**, 820–827.
- 30 M. Kaplan, T. Kilic, G. Guler, J. Mandli, A. Amine and M. Ozsoz, *Biosens. Bioelectron.*, 2017, **92**, 770–778.
- 31 D. Voccia, M. Sosnowska, F. Bettazzi, G. Roscigno, E. Fratini, V. De Franciscis, G. Condorelli, R. Chitta, F. D'Souza, W. Kutner and I. Palchetti, *Biosens. Bioelectron.*, 2017, **87**, 1012–1019.
- 32 J. L. Mott and A. M. Mohr, *Semin. Liver Dis.*, 2015, **35**, 3–11.

- 33 K. A. Cissell, S. Shrestha and S. K. Deo, *Anal. Chem.*, 2007, **79**, 4754–4761.
- 34 G. Rossetti, P. D. Dans, I. Gomez-Pinto, I. Ivani, C. Gonzalez and M. Orozco, *Nucleic Acids Res.*, 2015, **43**, 4309–4321.
- 35 X. Y. Piao, L. C. Sun, T. B. Zhang, Y. L. Gan and Y. F. Guan, *Acta Biochim. Pol.*, 2008, **55**, 713–720.
- 36 T. Naiser, O. Ehler, J. Kayser, T. Mai, W. Michel and A. Ott, *BMC Biotechnol.*, 2008, **8**, 48.
- 37 A. Bala and L. Górski, *Anal. Methods*, 2016, **8**, 236–244.
- 38 C. P. Price, *Br. Med. J.*, 2001, **322**, 1285–1288.
- 39 R. Deng, K. Zhang and J. Li, *Acc. Chem. Res.*, 2017, **50**, 1059–1068.
- 40 Y. Cheng, L. Dong, J. Zhang, Y. Zhao and Z. Li, *Analyst*, 2018, **143**, 1758–1774.
- 41 A. B. Steel, T. M. Herne and M. J. Tarlov, *Anal. Chem.*, 1998, **70**, 4670–4677.
- 42 J. Yao, Z. Zhang, Z. Deng, Y. Wang and Y. Guo, *Analyst*, 2017, **142**, 4116–4123.
- 43 M. Bartosik, R. Hrstka, E. Palecek and B. Vojtesek, *Anal. Chim. Acta*, 2014, **813**, 35–40.
- 44 Z. Gao and Y. H. Yu, *Biosens. Bioelectron.*, 2007, **22**, 933–940.
- 45 E. A. Lusi, M. Passamano, P. Guarascio, A. Scarpa and L. Schiavo, *Anal. Chem.*, 2009, **81**, 2819–2822.
- 46 F. Li, J. Peng, J. Wang, H. Tang, L. Tan, Q. Xie and S. Yao, *Biosens. Bioelectron.*, 2014, **54**, 158–164.
- 47 E. Eksin and A. Erdem, *J. Electroanal. Chem.*, 2018, **810**, 232–238.
- 48 Y.-X. Chen, K.-J. Huang and K.-X. Niu, *Biosens. Bioelectron.*, 2018, **99**, 612–624.
- 49 Q. Li, C. Batchelor-McAuley and R. G. Compton, *J. Phys. Chem. B*, 2010, **114**, 7423–7428.
- 50 F. Li, J. Peng, Q. Zheng, X. Guo, H. Tang and S. Yao, *Anal. Chem.*, 2015, **87**, 4806–4813.
- 51 M. Azimzadeh, M. Rahaie, N. Nasirizadeh, K. Ashtari and H. Naderi-Manesh, *Biosens. Bioelectron.*, 2016, **77**, 99–106.
- 52 H. A. Rafiee-Pour, M. Behpour and M. Keshavarz, *Biosens. Bioelectron.*, 2016, **77**, 202–207.
- 53 L. Tian, K. Qian, J. Qi, Q. Liu, C. Yao, W. Song and Y. Wang, *Biosens. Bioelectron.*, 2018, **99**, 564–570.
- 54 J. Guo, C. Yuan, Q. Yan, Q. Duan, X. Li and G. Yi, *Biosens. Bioelectron.*, 2018, **105**, 103–108.
- 55 T. Hou, W. Li, X. Liu and F. Li, *Anal. Chem.*, 2015, **87**, 11368–11374.
- 56 A. A. Gorodetsky, M. C. Buzzeo and J. K. Barton, *Bioconjugate Chem.*, 2008, **19**, 2285–2296.
- 57 M. N. Islam, M. K. Masud, N. T. Nguyen, V. Gopalan, H. R. Alamri, Z. A. Alothman, M. S. A. Hossain, Y. Yamauchi, A. K. Lam and M. J. A. Shiddiky, *Biosens. Bioelectron.*, 2017, **101**, 275–281.
- 58 C. R. Ispas, G. Crivat and S. Andreescu, *Anal. Lett.*, 2012, **45**, 168–186.
- 59 L. El Harrad, I. Bourais, H. Mohammadi and A. Amine, *Sensors*, 2018, **18**, 164.
- 60 J. Wang, *Chem. Rev.*, 2008, **108**, 814–825.
- 61 I. Palchetti, *Mini-Rev. Med. Chem.*, 2016, **16**, 1125–1133.
- 62 D. Zeng, Z. Wang, Z. Meng, P. Wang, L. San, W. Wang, A. Aldalbahi, L. Li, J. Shen and X. Mi, *ACS Appl. Mater. Interfaces*, 2017, **9**, 24118–24125.
- 63 T. Hu, L. Zhang, W. Wen, X. Zhang and S. Wang, *Biosens. Bioelectron.*, 2016, **77**, 451–456.
- 64 Z. Ge, M. Lin, P. Wang, H. Pei, J. Yan, J. Shi, Q. Huang, D. He, C. Fan and X. Zuo, *Anal. Chem.*, 2014, **86**, 2124–2130.
- 65 S. Hofmann, Y. Huang, P. Paulicka, A. Kappel, H. A. Katus, A. Keller, B. Meder, C. F. Stahler and W. Gumbrecht, *Anal. Chem.*, 2015, **87**, 12104–12111.
- 66 M. Lin, Y. Wen, L. Li, H. Pei, G. Liu, H. Song, X. Zuo, C. Fan and Q. Huang, *Anal. Chem.*, 2014, **86**, 2285–2288.
- 67 F. F. Cheng, J. J. Zhang, T. T. He, J. J. Shi, E. S. Abdel-Halim and J. J. Zhu, *Analyst*, 2014, **139**, 3860–3865.
- 68 N. Xia, Y. Zhang, X. Wei, Y. Huang and L. Liu, *Anal. Chim. Acta*, 2015, **878**, 95–101.
- 69 Z. Gao and Y. Peng, *Biosens. Bioelectron.*, 2011, **26**, 3768–3773.
- 70 T. Kilic, S. N. Topkaya, D. Ozkan Ariksoysal, M. Ozsoz, P. Ballar, Y. Erac and O. Gozen, *Biosens. Bioelectron.*, 2012, **38**, 195–201.
- 71 H. Yin, Y. Zhou, C. Chen, L. Zhu and S. Ai, *Analyst*, 2012, **137**, 1389–1395.
- 72 Y. X. Chen, W. J. Zhang, K. J. Huang, M. Zheng and Y. C. Mao, *Analyst*, 2017, **142**, 4843–4851.
- 73 Y.-X. Chen, X. Wu and K.-J. Huang, *Sens. Actuators, B*, 2018, **270**, 179–186.
- 74 F. Bettazzi, E. Hamid-Asl, C. L. Esposito, C. Quintavalle, N. Formisano, S. Laschi, S. Catuogno, M. Iaboni, G. Marrazza, M. Mascini, L. Cerchia, V. De Franciscis, G. Condorelli and I. Palchetti, *Anal. Bioanal. Chem.*, 2013, **405**, 1025–1034.
- 75 S. Campuzano, R. M. Torrente-Rodriguez, E. Lopez-Hernandez, F. Conzuelo, R. Granados, J. M. Sanchez-Puelles and J. M. Pingarron, *Angew. Chem., Int. Ed.*, 2014, **53**, 6168–6171.
- 76 Z. Gao, *Analyst*, 2012, **137**, 1674–1679.
- 77 W. Ma, B. Situ, W. Lv, B. Li, X. Yin, P. Vadgama, L. Zheng and W. Wang, *Biosens. Bioelectron.*, 2016, **80**, 344–351.
- 78 Y. Zhou, H. Yin, J. Li, B. Li, X. Li, S. Ai and X. Zhang, *Biosens. Bioelectron.*, 2016, **79**, 79–85.
- 79 Y. Wu, K. Sheng, Y. Liu, Q. Yu and B. Ye, *Anal. Chim. Acta*, 2016, **948**, 1–8.
- 80 S. K. Silverman, *Trends Biochem. Sci.*, 2016, **41**, 595–609.
- 81 M. Liu, D. Chang and Y. Li, *Acc. Chem. Res.*, 2017, **50**, 2273–2283.
- 82 I. Willner, B. Shlyahovsky, M. Zayats and B. Willner, *Chem. Soc. Rev.*, 2008, **37**, 1153–1165.
- 83 J. Kosman and B. Juskowiak, *Anal. Chim. Acta*, 2011, **707**, 7–17.
- 84 M. Mahdiannasser and Z. Karami, *Biosens. Bioelectron.*, 2018, **107**, 123–144.
- 85 R. Stoltenburg, C. Reinemann and B. Strehlitz, *Biomol. Eng.*, 2007, **24**, 381–403.

- 86 A. D. Ellington and J. W. Szostak, *Nature*, 1990, **346**, 818.
- 87 X. Cheng, X. Liu, T. Bing, Z. Cao and D. Shangguan, *Biochemistry*, 2009, **48**, 7817–7823.
- 88 L. Ding, L. Zhang, H. Yang, H. Liu, S. Ge and J. Yu, *Sens. Actuators, B*, 2018, **268**, 210–216.
- 89 D. Kong, S. Bi, Z. Wang, J. Xia and F. Zhang, *Anal. Chem.*, 2016, **88**, 10667–10674.
- 90 L. Liu, C. Song, Z. Zhang, J. Yang, L. Zhou, X. Zhang and G. Xie, *Biosens. Bioelectron.*, 2015, **70**, 351–357.
- 91 K. Shi, B. Dou, J. Yang, R. Yuan and Y. Xiang, *Anal. Chim. Acta*, 2016, **916**, 1–7.
- 92 F. F. Cheng, N. Jiang, X. Li, L. Zhang, L. Hu, X. Chen, L. P. Jiang, E. S. Abdel-Halim and J. J. Zhu, *Biosens. Bioelectron.*, 2016, **85**, 891–896.
- 93 X. Meng, Y. Zhou, Q. Liang, X. Qu, Q. Yang, H. Yin and S. Ai, *Analyst*, 2013, **138**, 3409–3415.
- 94 Y. Yu, Z. Chen, L. Shi, F. Yang, J. Pan, B. Zhang and D. Sun, *Anal. Chem.*, 2014, **86**, 8200–8205.
- 95 D. A. Smith, L. J. Newbury, G. Drago, T. Bowen and J. E. Redman, *Sens. Actuators, B*, 2017, **253**, 335–341.
- 96 M. Labib, S. M. Ghobadloo, N. Khan, D. M. Kolpashchikov and M. V. Berezovski, *Anal. Chem.*, 2013, **85**, 9422–9427.
- 97 M. Wang, Z. Fu, B. Li, Y. Zhou, H. Yin and S. Ai, *Anal. Chem.*, 2014, **86**, 5606–5610.
- 98 H. V. Tran, B. Piro, S. Reisberg, H. T. Duc and M. C. Pham, *Anal. Chem.*, 2013, **85**, 8469–8474.
- 99 K. M. Koo, L. G. Carrascosa, M. J. Shiddiky and M. Trau, *Anal. Chem.*, 2016, **88**, 2000–2005.
- 100 K. Boriachek, M. Umer, M. N. Islam, V. Gopalan, A. K. Lam, N. T. Nguyen and M. J. A. Shiddiky, *Analyst*, 2018, **143**, 1662–1669.
- 101 M. Holzinger, A. Le Goff and S. Cosnier, *Front. Chem.*, 2014, **2**, 63.
- 102 S. E. Kleijn, S. C. Lai, M. T. Koper and P. R. Unwin, *Angew. Chem., Int. Ed.*, 2014, **53**, 3558–3586.
- 103 M. Pumera, S. Sánchez, I. Ichinose and J. Tang, *Sens. Actuators, B*, 2007, **123**, 1195–1205.
- 104 N. Xia and L. Zhang, *Materials*, 2014, **7**, 5366–5384.
- 105 T. Kangkamano, A. Numnuam, W. Limbut, P. Kanatharana, T. Vilaivan and P. Thavarungkul, *Biosens. Bioelectron.*, 2018, **102**, 217–225.
- 106 C. Yang, K. Shi, B. Dou, Y. Xiang, Y. Chai and R. Yuan, *ACS Appl. Mater. Interfaces*, 2015, **7**, 1188–1193.
- 107 Y. Wang, X. Zhang, L. Zhao, T. Bao, W. Wen, X. Zhang and S. Wang, *Biosens. Bioelectron.*, 2017, **98**, 386–391.
- 108 H. Dong, S. Jin, H. Ju, K. Hao, L. P. Xu, H. Lu and X. Zhang, *Anal. Chem.*, 2012, **84**, 8670–8674.
- 109 N. Yu, Z. Wang, C. Wang, J. Han and H. Bu, *Anal. Chim. Acta*, 2017, **962**, 24–31.
- 110 H. Wang, Y. Jian, Q. Kong, H. Liu, F. Lan, L. Liang, S. Ge and J. Yu, *Sens. Actuators, B*, 2018, **257**, 561–569.
- 111 Z. Lu, H. Tang, D. Wu, Y. Xia, M. Wu, X. Yi, H. Li and J. Wang, *Biosens. Bioelectron.*, 2016, **86**, 502–507.
- 112 J. Wang, X. Yi, H. Tang, H. Han, M. Wu and F. Zhou, *Anal. Chem.*, 2012, **84**, 6400–6406.
- 113 F. F. Cheng, T. T. He, H. T. Miao, J. J. Shi, L. P. Jiang and J. J. Zhu, *ACS Appl. Mater. Interfaces*, 2015, **7**, 2979–2985.
- 114 Y.-H. Yuan, B.-Z. Chi, S.-H. Wen, R.-P. Liang, Z.-M. Li and J.-D. Qiu, *Biosens. Bioelectron.*, 2017, **97**, 325–331.
- 115 Y. H. Yuan, Y. D. Wu, B. Z. Chi, S. H. Wen, R. P. Liang and J. D. Qiu, *Biosens. Bioelectron.*, 2017, **97**, 325–331.
- 116 H. V. Tran, B. Piro, S. Reisberg, L. D. Tran, H. T. Duc and M. C. Pham, *Biosens. Bioelectron.*, 2013, **49**, 164–169.
- 117 N. Xia, L. Zhang, G. Wang, Q. Feng and L. Liu, *Biosens. Bioelectron.*, 2013, **47**, 461–466.
- 118 W. Zhu, X. Su, X. Gao, Z. Dai and X. Zou, *Biosens. Bioelectron.*, 2014, **53**, 414–419.
- 119 Z. Wang, J. Zhang, Y. Guo, X. Wu, W. Yang, L. Xu, J. Chen and F. Fu, *Biosens. Bioelectron.*, 2013, **45**, 108–113.
- 120 M. Vert, Y. Doi, K.-H. Hellwich, M. Hess, P. Hodge, P. Kubisa, M. Rinaudo and F. Schué, *Pure Appl. Chem.*, 2012, **84**, 377–410.
- 121 R. Tavallaie, J. McCarroll, M. Le Grand, N. Ariotti, W. Schuhmann, E. Bakker, R. D. Tilley, D. B. Hibbert, M. Kavallaris and J. J. Gooding, *Nat. Nanotechnol.*, 2018, DOI: 10.1038/s41565-018-0232-x.
- 122 J. Gómez-Pastora, X. Xue, I. H. Karampelas, E. Bringas, E. P. Furlani and I. Ortiz, *Sep. Purif. Technol.*, 2017, **172**, 16–31.
- 123 E. Paleček and M. Fojta, *Talanta*, 2007, **74**, 276–290.
- 124 P. Yáñez-Sedeño, S. Campuzano and J. M. Pingarrón, *Sensors*, 2016, **16**, 1585.
- 125 S. Liu, W. Su, Z. Li and X. Ding, *Biosens. Bioelectron.*, 2015, **71**, 57–61.
- 126 P. Miao, B. Wang, X. Chen, X. Li and Y. Tang, *ACS Appl. Mater. Interfaces*, 2015, **7**, 6238–6243.
- 127 P. Miao, B. Wang, F. Meng, J. Yin and Y. Tang, *Bioconjugate Chem.*, 2015, **26**, 602–607.
- 128 H. Pei, X. Zuo, D. Pan, J. Shi, Q. Huang and C. Fan, *NPG Asia Mater.*, 2013, **5**, e51–e51.
- 129 R. P. Goodman, R. M. Berry and A. J. Turberfield, *Chem. Commun.*, 2004, 1372–1373, DOI: 10.1039/B402293A.
- 130 N. Xie, S. Liu, X. Yang, X. He, J. Huang and K. Wang, *Analyst*, 2017, **142**, 3322–3332.
- 131 N. Mitchell, R. Schlapak, M. Kastner, D. Armitage, W. Chrzanowski, J. Riener, P. Hinterdorfer, A. Ebner and S. Howorka, *Angew. Chem., Int. Ed.*, 2009, **48**, 525–527.
- 132 H. Pei, N. Lu, Y. Wen, S. Song, Y. Liu, H. Yan and C. Fan, *Adv. Mater.*, 2010, **22**, 4754–4758.
- 133 P. Gai, C. Gu, H. Li, X. Sun and F. Li, *Anal. Chem.*, 2017, **89**, 12293–12298.
- 134 C. Gu, P. Gai, X. Liu, J. Liu and F. Li, *Sens. Actuators, B*, 2018, **270**, 1–8.
- 135 L. Garibyan and N. Avashia, *J. Invest. Dermatol.*, 2013, **133**, 1–4.
- 136 M. M. Ali, F. Li, Z. Zhang, K. Zhang, D. K. Kang, J. A. Ankrum, X. C. Le and W. Zhao, *Chem. Soc. Rev.*, 2014, **43**, 3324–3341.
- 137 Q. Li, F. Zeng, N. Lyu and J. Liang, *Analyst*, 2018, **143**, 2304–2309.

- 138 X. Qiu, H. Zhang, H. Yu, T. Jiang and Y. Luo, *Trends Biotechnol.*, 2015, **33**, 180–188.
- 139 C. Yang, B. Dou, K. Shi, Y. Chai, Y. Xiang and R. Yuan, *Anal. Chem.*, 2014, **86**, 11913–11918.
- 140 A. D. Castaneda, N. J. Brenes, A. Kondajji and R. M. Crooks, *J. Am. Chem. Soc.*, 2017, **139**, 7657–7664.
- 141 T. Fu, Y. Lyu, H. Liu, R. Peng, X. Zhang, M. Ye and W. Tan, *Trends Biochem. Sci.*, 2018, **43**, 547–560.
- 142 S. G. Harroun, C. Prévost-Tremblay, D. Lauzon, A. Desrosiers, X. Wang, L. Pedro and A. Vallée-Bélisle, *Nanoscale*, 2018, **10**, 4607–4641.
- 143 R. M. Dirks and N. A. Pierce, *Proc. Natl. Acad. Sci. U. S. A.*, 2004, **101**, 15275.
- 144 D. Evanko, *Nat. Methods*, 2004, **1**, 186.
- 145 S. Bi, S. Yue and S. Zhang, *Chem. Soc. Rev.*, 2017, **46**, 4281–4298.
- 146 L. Tian, J. Qi, O. Oderinde, C. Yao, W. Song and Y. Wang, *Biosens. Bioelectron.*, 2018, **110**, 110–117.
- 147 H. Zhang, Q. Wang, X. Yang, K. Wang, Q. Li, Z. Li, L. Gao, W. Nie and Y. Zheng, *Analyst*, 2017, **142**, 389–396.
- 148 P. Miao, B. Wang, Z. Yu, J. Zhao and Y. Tang, *Biosens. Bioelectron.*, 2015, **63**, 365–370.
- 149 S. Nakayama, L. Yan and H. O. Sintim, *J. Am. Chem. Soc.*, 2008, **130**, 12560–12561.
- 150 J. Zhang, J. H. Chen, R. C. Chen, G. N. Chen and F. F. Fu, *Biosens. Bioelectron.*, 2009, **25**, 815–819.
- 151 C. Y. Hong, X. Chen, T. Liu, J. Li, H. H. Yang, J. H. Chen and G. N. Chen, *Biosens. Bioelectron.*, 2013, **50**, 132–136.
- 152 M. Labib, N. Khan, S. M. Ghobadloo, J. Cheng, J. P. Pezacki and M. V. Berezovski, *J. Am. Chem. Soc.*, 2013, **135**, 3027–3038.
- 153 C. Li, D. Wu, X. Hu, Y. Xiang, Y. Shu and G. Li, *Anal. Chem.*, 2016, **88**, 7583–7590.
- 154 L. Liu, N. Xia, H. Liu, X. Kang, X. Liu, C. Xue and X. He, *Biosens. Bioelectron.*, 2014, **53**, 399–405.
- 155 C. Ma, M. Zhang, S. Chen, C. Liang and C. Shi, *Analyst*, 2016, **141**, 2883–2886.
- 156 D. Voccia, F. Bettazzi, E. Fratini, D. Berti and I. Palchetti, *Anal. Bioanal. Chem.*, 2016, **408**, 7271–7281.
- 157 Y. Zhang, Y. Yan, W. Chen, W. Cheng, S. Li, X. Ding, D. Li, H. Wang, H. Ju and S. Ding, *Biosens. Bioelectron.*, 2015, **68**, 343–349.
- 158 C. Pohlmann and M. Sprinzi, *Anal. Chem.*, 2010, **82**, 4434–4440.
- 159 Z. Cai, Y. Song, Y. Wu, Z. Zhu, C. J. Yang and X. Chen, *Biosens. Bioelectron.*, 2013, **41**, 783–788.
- 160 T. Kilic, S. Nur Topkaya and M. Ozsoz, *Biosens. Bioelectron.*, 2013, **48**, 165–171.
- 161 M. Labib, N. Khan and M. V. Berezovski, *Anal. Chem.*, 2015, **87**, 1395–1403.
- 162 L. Liu, Y. Chang, N. Xia, P. Peng, L. Zhang, M. Jiang, J. Zhang and L. Liu, *Biosens. Bioelectron.*, 2017, **94**, 235–242.
- 163 Z. Gao and Z. Yang, *Anal. Chem.*, 2006, **78**, 1470–1477.
- 164 X. Wu, Y. Chai, R. Yuan, H. Su and J. Han, *Analyst*, 2013, **138**, 1060–1066.
- 165 Y. Li, R. Tian, X. Zheng and R. Huang, *Anal. Chim. Acta*, 2016, **934**, 59–65.
- 166 M. Mohammadniaei, T. Lee, J. Yoon, D. Lee and J. W. Choi, *Biosens. Bioelectron.*, 2017, **98**, 292–298.
- 167 K. Shi, B. Dou, C. Yang, Y. Chai, R. Yuan and Y. Xiang, *Anal. Chem.*, 2015, **87**, 8578–8583.
- 168 F. Xuan, T. W. Fan and I. M. Hsing, *ACS Nano*, 2015, **9**, 5027–5033.